JP4557098B2 - Stable 6-amidino-2-naphthyl 4-guanidinobenzoate acid addition salt preparation and method for producing the same - Google Patents

Stable 6-amidino-2-naphthyl 4-guanidinobenzoate acid addition salt preparation and method for producing the same Download PDF

Info

Publication number
JP4557098B2
JP4557098B2 JP09208999A JP9208999A JP4557098B2 JP 4557098 B2 JP4557098 B2 JP 4557098B2 JP 09208999 A JP09208999 A JP 09208999A JP 9208999 A JP9208999 A JP 9208999A JP 4557098 B2 JP4557098 B2 JP 4557098B2
Authority
JP
Japan
Prior art keywords
amidino
naphthyl
guanidinobenzoate
acid addition
addition salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP09208999A
Other languages
Japanese (ja)
Other versions
JP2000290179A (en
Inventor
徹 夏賀
昭保 吉岡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Priority to JP09208999A priority Critical patent/JP4557098B2/en
Publication of JP2000290179A publication Critical patent/JP2000290179A/en
Application granted granted Critical
Publication of JP4557098B2 publication Critical patent/JP4557098B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

【0001】
【発明の属する技術分野】
本発明は、安定な6−アミジノ−2−ナフチル 4−グアニジノベンゾエート酸付加塩製剤ならびにその製造方法に関する。
【0002】
【従来の技術】
6−アミジノ−2−ナフチル 4−グアニジノベンゾエートの酸付加塩は、蛋白分解酵素阻害作用をもち、血液凝固・線溶系(トロンビン、XIIa、Xa、VIIa、プラスミン)、カリクレイン−キニン系(カリクレイン)、補体系(C1r、C1s、B、D)および膵酵素(トリプシン、膵カリクレイン)に対する強力な阻害作用を有することが知られている。
【0003】
そのトロンビンに対する阻害はアンチトロンビンIIIに依存せず、血液凝固時間も強力に延長し、さらに血小板凝集に対する強い抑制効果を有する。このことから、汎発性血管内血液凝固症(DIC)に対する強い有用性が認められている。
【0004】
また、トリプシンおよびα−マクログロブリン結合トリプシンの双方に対する強力な阻害作用、及びホスホリパーゼAに対する阻害作用から、膵炎の急性症状の改善への高い有用性が確認されている。
【0005】
6−アミジノ−2−ナフチル 4−グアニジノベンゾエート酸付加塩は水溶液中では不安定であることから、用時溶解の製剤として用いられている。
【0006】
【発明が解決しようとする課題】
本発明の目的は、水溶液中で不安定な6−アミジノ−2−ナフチル 4−グアニジノベンゾエート酸付加塩を、溶解後長期にわたって安定に保存できる6−アミジノ−2−ナフチル 4−グアニジノベンゾエート酸付加塩製剤およびその製造方法を提供することにある。
【0007】
【課題を解決するための手段】
上記問題点を解決すべく鋭意研究を重ねた結果、6−アミジノ−2−ナフチル4−グアニジノベンゾエート酸付加塩と共にコハク酸を水に溶解し、この水溶液を凍結乾燥することによって、安定な凍結乾燥製剤が得られることを見出した。
【0008】
本発明において、6−アミジノ−2−ナフチル 4−グアニジノベンゾエート酸付加塩としては、6−アミジノ−2−ナフチル 4−グアニジノベンゾエート1モルに対して、塩酸、硫酸、リン酸等の無機酸、または、酢酸、乳酸、クエン酸、メタンスルホン酸、4−トルエンスルホン酸、コハク酸、フマル酸、マレイン酸等の有機酸等の医薬として使用可能な酸が、2当量付加したものが用いられる。
【0009】
本発明においては、このような6−アミジノ−2−ナフチル 4−グアニジノベンゾエート酸付加塩とコハク酸を、重量比で15〜5:1の割合、より好ましくは10:1の割合で加えて凍結乾燥をする。
【0010】
この凍結乾燥に際しては、D−マンニトール、乳糖および白糖の1種または2種以上を、6−アミジノ−2−ナフチル 4−グアニジノベンゾエート酸付加塩の1〜3倍量、より好ましくは約2倍量程度、配合することが望ましい。
【0011】
これらは適当量の水に溶解して、ガラスバイアルに分注し、凍結乾燥するのがよい。この時、用いる水の量は、通常6−アミジノ−2−ナフチル 4−グアニジノベンゾエート酸付加塩重量の20〜200倍程度である。
【0012】
また、凍結乾燥は常法によって行う。凍結乾燥条件としては、例えば、予備凍結;−50〜−5℃で5〜20時間、次に一次乾燥;−10℃〜10℃で20〜50時間、二次乾燥;10〜30℃で10〜30時間の順に行うのが望ましい。
具体的には、−45℃で8時間の予備凍結の後、一次乾燥として0℃で40時間、二次乾燥として25℃、15時間程度処理するのがよい。
【0013】
このように凍結乾燥の際にも長時間を有することから、水溶液中で不安定な6−アミジノ−2−ナフチル 4−グアニジノベンゾエート酸付加塩を、本発明方法で凍結乾燥すると、製造工程中の分解を最小限に止めることが可能となり、安定な製剤を提供できる。さらに、本発明によって製造した6−アミジノ−2−ナフチル 4−グアニジノベンゾエート酸付加塩製剤は用時溶解後も24時間以上安定に保つことができる。
【0014】
次に、実施例をあげて、本発明をさらに詳細に説明する。
【0015】
【実施例】
6−アミジノ−2−ナフチル 4−グアニジノベンゾエート ジメタンスルフォネート(C191752・2CH3SO3H)20g、D−マンニトール40g及びコハク酸2gを水に溶かし、正確に2Lとした。この液を0.45μmのフィルターでろ過し、1mLずつガラスバイアルに分注した後、凍結乾燥(−45℃で8時間の予備凍結の後、一次乾燥として0℃で40時間、二次乾燥として25℃で15時間)を行った。終了後、打栓し、アルミキャップで巻き締めをした。
【0016】
このようにして製造した6−アミジノ−2−ナフチル 4−グアニジノベンゾエート−ジメタンスルフォネート凍結乾燥製剤を、水10mLで溶解し、この液2μLを正確にとり、次の条件で液体クロマトグラフ法により、6−アミジノ−2−ナフチル 4−グアニジノベンゾエートのピーク面積を測定し、6−アミジノ−2−ナフチル 4−グアニジノベンゾエートの残存率を求めた。
【0017】
以下に液体クロマトグラフ法の操作条件を示した。
検出器:紫外吸光光度計(測定波長:261nm)
カラム:YMC−Pack ODS−AM AM−303
(5μm、4.6mm×250mm、(株)YMC製)
カラム温度:35℃付近の一定温度
移動相:薄めたリン酸(1→1000)/アセトニトリル混液(9:1)
注入量:2μL
流量:毎分1mL
【0018】
その結果、溶解直後は99.90%、1時間後99.85%、2時間後99.86%、24時間後99.62%であり、安定であった。
[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a stable 6-amidino-2-naphthyl 4-guanidinobenzoate acid addition salt preparation and a method for producing the same.
[0002]
[Prior art]
6-Amidino-2-naphthyl 4-guanidinobenzoate acid addition salt has a proteolytic enzyme inhibitory action, blood coagulation / fibrinolytic system (thrombin, XIIa, Xa, VIIa, plasmin), kallikrein-kinin system (kallikrein), It is known to have a potent inhibitory action on the complement system (C 1r , C 1s , B, D) and pancreatic enzymes (trypsin, pancreatic kallikrein).
[0003]
The inhibition of thrombin does not depend on antithrombin III, the blood coagulation time is strongly prolonged, and it has a strong inhibitory effect on platelet aggregation. From this, strong usefulness against generalized intravascular blood coagulation (DIC) is recognized.
[0004]
In addition, a strong inhibitory action on both trypsin and α 2 -macroglobulin-bound trypsin and an inhibitory action on phospholipase A 2 have been confirmed to be highly useful for improving acute symptoms of pancreatitis.
[0005]
Since 6-amidino-2-naphthyl 4-guanidinobenzoate acid addition salt is unstable in an aqueous solution, it is used as a preparation which is dissolved at the time of use.
[0006]
[Problems to be solved by the invention]
The object of the present invention is to provide 6-amidino-2-naphthyl 4-guanidinobenzoate acid addition salt which can be stably stored for a long time after dissolution of 6-amidino-2-naphthyl 4-guanidinobenzoate acid addition salt which is unstable in aqueous solution It is to provide a preparation and a production method thereof.
[0007]
[Means for Solving the Problems]
As a result of extensive research to solve the above problems, stable lyophilization is achieved by dissolving succinic acid in water together with 6-amidino-2-naphthyl 4-guanidinobenzoate acid addition salt and freeze-drying this aqueous solution. It was found that a formulation was obtained.
[0008]
In the present invention, the 6-amidino-2-naphthyl 4-guanidinobenzoate acid addition salt is an inorganic acid such as hydrochloric acid, sulfuric acid, phosphoric acid or the like with respect to 1 mol of 6-amidino-2-naphthyl 4-guanidinobenzoate, or , Acetic acid, lactic acid, citric acid, methanesulfonic acid, 4-toluenesulfonic acid, succinic acid, fumaric acid, maleic acid, and other organic acids that can be used as pharmaceuticals are used.
[0009]
In the present invention, such 6-amidino-2-naphthyl 4-guanidinobenzoate acid addition salt and succinic acid are added at a weight ratio of 15 to 5: 1, more preferably 10: 1, and frozen. Dry.
[0010]
In this lyophilization, one or more of D-mannitol, lactose and sucrose are added in an amount of 1 to 3 times, more preferably about 2 times the amount of 6-amidino-2-naphthyl 4-guanidinobenzoate acid addition salt. It is desirable to blend to the extent.
[0011]
These may be dissolved in an appropriate amount of water, dispensed into glass vials, and lyophilized. At this time, the amount of water used is usually about 20 to 200 times the weight of 6-amidino-2-naphthyl 4-guanidinobenzoate acid addition salt.
[0012]
Freeze-drying is performed by a conventional method. As lyophilization conditions, for example, preliminary freezing; −50 to −5 ° C. for 5 to 20 hours, then primary drying; −10 ° C. to 10 ° C. for 20 to 50 hours, secondary drying; It is desirable to carry out in order of ~ 30 hours.
Specifically, after preliminary freezing at −45 ° C. for 8 hours, primary drying may be performed at 0 ° C. for 40 hours, and secondary drying may be performed at 25 ° C. for about 15 hours.
[0013]
Since lyophilization has a long time as described above, 6-amidino-2-naphthyl 4-guanidinobenzoate acid addition salt which is unstable in an aqueous solution is freeze-dried by the method of the present invention. Degradation can be minimized and a stable formulation can be provided. Furthermore, the 6-amidino-2-naphthyl 4-guanidinobenzoate acid addition salt preparation produced according to the present invention can be kept stable for more than 24 hours after dissolution at the time of use.
[0014]
Next, the present invention will be described in more detail with reference to examples.
[0015]
【Example】
6-amidino-2-naphthyl 4-guanidino benzoate dimethyl chest Gandolfo sulfonate (C 19 H 17 N 5 O 2 · 2CH 3 SO 3 H) 20g, a D- mannitol 40g and succinic acid 2g was dissolved in water, and accurately 2L did. This solution is filtered through a 0.45 μm filter, dispensed in 1 mL portions into glass vials, and then freeze-dried (preliminary freezing at −45 ° C. for 8 hours, followed by primary drying at 0 ° C. for 40 hours, secondary drying) 15 hours at 25 ° C.). After completion, it was stoppered and tightened with an aluminum cap.
[0016]
The 6-amidino-2-naphthyl 4-guanidinobenzoate-dimethanesulfonate freeze-dried preparation thus prepared was dissolved in 10 mL of water, and 2 μL of this solution was accurately taken, and subjected to liquid chromatography under the following conditions: The peak area of 6-amidino-2-naphthyl 4-guanidinobenzoate was measured to determine the residual ratio of 6-amidino-2-naphthyl 4-guanidinobenzoate.
[0017]
The operating conditions of the liquid chromatography method are shown below.
Detector: UV absorptiometer (measurement wavelength: 261 nm)
Column: YMC-Pack ODS-AM AM-303
(5 μm, 4.6 mm × 250 mm, manufactured by YMC Corporation)
Column temperature: constant temperature around 35 ° C. Mobile phase: diluted phosphoric acid (1 → 1000) / acetonitrile mixture (9: 1)
Injection volume: 2 μL
Flow rate: 1 mL per minute
[0018]
As a result, 99.90% immediately after dissolution, 99.85% after 1 hour, 99.86% after 2 hours, and 99.62% after 24 hours, it was stable.

Claims (2)

6−アミジノ−2−ナフチル 4−グアニジノベンゾエート(C1917)酸付加塩15〜5部に対し、コハク酸1部、D−マンニトール、乳糖および白糖の1種または2種以上の35〜5部を、20〜200倍量の水に溶解し、凍結乾燥して得られた、溶解後24時間にわたり殆ど分解を認めないことを特徴とする安定な6−アミジノ−2−ナフチル 4−グアニジノベンゾエート酸付加塩凍結乾燥製剤。To 6-amidino-2-naphthyl 4-guanidino benzoate (C 19 H 17 N 5 O 2) acid addition salts 15-5 parts, 1 part of succinic acid, D- mannitol, one or more of lactose and white sugar A stable 6-amidino-2-naphthyl obtained by dissolving 35 to 5 parts of the above in 20 to 200 times the amount of water and freeze-drying, and hardly decomposes for 24 hours after dissolution 4-Guanidinobenzoate acid addition salt lyophilized formulation. 6−アミジノ−2−ナフチル 4−グアニジノベンゾエート酸付加塩15〜5部に対し、コハク酸1部、D−マンニトール、乳糖および白糖の1種または2種以上の35〜5部を、20〜200倍量の水に溶解し、凍結乾燥することからなる、溶解後24時間にわたり殆ど分解を認めないことを特徴とする安定な6−アミジノ−2−ナフチル 4−グアニジノベンゾエート酸付加塩凍結乾燥製剤の製造方法。To 15 to 5 parts of 6-amidino-2-naphthyl 4-guanidino benzoate acid addition salt, 1 part of succinic acid, D- mannitol, one or more of 35-5 parts of lactose and white sugar, from 20 to 200 A stable 6-amidino-2-naphthyl 4-guanidinobenzoate acid addition salt freeze-dried preparation characterized by dissolving in double volume of water and freeze-drying, with almost no degradation over 24 hours after dissolution Production method.
JP09208999A 1999-03-31 1999-03-31 Stable 6-amidino-2-naphthyl 4-guanidinobenzoate acid addition salt preparation and method for producing the same Expired - Fee Related JP4557098B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP09208999A JP4557098B2 (en) 1999-03-31 1999-03-31 Stable 6-amidino-2-naphthyl 4-guanidinobenzoate acid addition salt preparation and method for producing the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP09208999A JP4557098B2 (en) 1999-03-31 1999-03-31 Stable 6-amidino-2-naphthyl 4-guanidinobenzoate acid addition salt preparation and method for producing the same

Publications (2)

Publication Number Publication Date
JP2000290179A JP2000290179A (en) 2000-10-17
JP4557098B2 true JP4557098B2 (en) 2010-10-06

Family

ID=14044728

Family Applications (1)

Application Number Title Priority Date Filing Date
JP09208999A Expired - Fee Related JP4557098B2 (en) 1999-03-31 1999-03-31 Stable 6-amidino-2-naphthyl 4-guanidinobenzoate acid addition salt preparation and method for producing the same

Country Status (1)

Country Link
JP (1) JP4557098B2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11510170A (en) * 1995-07-27 1999-09-07 ジェネンテック インコーポレーテッド Protein Formula
JP2000510813A (en) * 1995-02-06 2000-08-22 ジェネテイックス・インスティテュート・インコーポレイテッド Formulation for IL-12

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4062933A (en) * 1975-05-27 1977-12-13 Mallinckrodt, Inc. Colloidal compositions with protective agents suitable for radioactive labeling
JPS5753454A (en) * 1980-09-16 1982-03-30 Torii Yakuhin Kk Guanidinobenzoate and anticomplementary agent
JP2937135B2 (en) * 1995-09-13 1999-08-23 日本新薬株式会社 PGE1-containing freeze-dried preparation and manufacturing method

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000510813A (en) * 1995-02-06 2000-08-22 ジェネテイックス・インスティテュート・インコーポレイテッド Formulation for IL-12
JPH11510170A (en) * 1995-07-27 1999-09-07 ジェネンテック インコーポレーテッド Protein Formula

Also Published As

Publication number Publication date
JP2000290179A (en) 2000-10-17

Similar Documents

Publication Publication Date Title
US8404724B2 (en) Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor
US20020065303A1 (en) Bivalent phenylene inhibitors of factor Xa
US20020058677A1 (en) Isoquinolone inhibitors of factor Xa
US20040067938A1 (en) Quaternary amines and related inhibitors of factor xa
PL195642B1 (en) Improved methods of processing activated protein c
US20020013314A1 (en) 3,4-dihydro-2H-benzo[1,4]oxazine inhibitors of factor Xa
JP2009024015A (en) Cyclic peptide binding to urokinase-type plasminogen activator receptor
JPH10503176A (en) 3-Amino-2-oxo-1-piperidineacetic acid derivatives as enzyme inhibitors
WO2001057020A1 (en) INDOLE AND BENZIMIDAZOLE INHIBITORS OF FACTOR Xa
US6777413B2 (en) 2-[1H]-quinolone and 2-[1H]-quinoxalone inhibitors of factor Xa
CN1332939C (en) Novel compounds inhibiting factor Xa activity
US20020052368A1 (en) Oxindole inhibitors of factor Xa
JP4557098B2 (en) Stable 6-amidino-2-naphthyl 4-guanidinobenzoate acid addition salt preparation and method for producing the same
US9745363B2 (en) Compositions and methods for inhibiting thrombogenesis
US20050096323A1 (en) Diketopiperazine derivatives to inhibit thrombin
KR20020020728A (en) Factor VIIa inhibitors
AU2005263600A1 (en) Novel compounds that inhibit factor Xa activity
US4851345A (en) Fibrinophilic urokinase complex and method for production thereof
MX2009001990A (en) TARTRATE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS.
Puri et al. Modulation of thrombin‐induced platelet aggregation by inhibition of calpain by a synthetic peptide derived from the thiol‐protease inhibitory sequence of kininogens and S‐(3‐nitro‐2‐pyridinesulfenyl)‐cysteine
US20020019394A1 (en) Bicyclic sulfonyl amino inhibitors of factor Xa
ES2280333T3 (en) BICYCLE DERIVATIVES OF AMINOPIRAZONES, ITS PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
AU632654B2 (en) Freeze-dried preparation of etoposide-2-dimethylamino compound
CN113384526A (en) Stable apixaban oral solution preparation and preparation method thereof
US20030186972A1 (en) Isoquinolone inhibitors of factor Xa

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20050628

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060306

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091117

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100118

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20100118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100630

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100713

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130730

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130730

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees